Aldosterone and the Metabolic Syndrome

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (137 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: greater thanto determinehgthe purposepurpose of
  Phrases that lowered it: arthritismalessubjectsplasmatransaminase
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 14.3% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.4% (lowers risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 74.7% (lowers risk) · Drug's FDA history
• Primary purpose: prevention (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports before start: 45776 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 10346 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 16 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 14 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Eplerenone on Endothelial Function in Metabolic Syndrome NCT01319344 · started 2010 · scored riskier than 84% of active trials completed
• The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production NCT02871648 · started 2016 · scored riskier than 4% of active trials completed
• Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin NCT02811055 · started 2017 · scored riskier than 30% of active trials completed
• A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. NCT05884866 · started 2023 · scored riskier than 48% of active trials completed
• Prevention of Metabolic Complications of Glucocorticoid Excess NCT01319994 · started 2012 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.